Company news
IMPACT Therapeutics, Inc. news
Latest news releases, newest first.
Voluntary announcement - poster presentation of latest clinical data for senaparib and PARP1-selective inhibitors IMP1734 and IMP1707 at 2026 ESMO congress
October 23, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 5, 2026
Voluntary announcement - positive CHMP opinion for senaparib, as potential first-line maintenance treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer
September 18, 2026
2026 Interim Report
September 13, 2026
IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
July 31, 2026
Articles of association
June 25, 2026
Next Day Disclosure Return
June 10, 2026